Abstract | OBJECTIVE: DESIGN: Retrospective cohort study. SETTING: PATIENT(S): INTERVENTION(S): None. MAIN OUTCOME MEASURE(S):
Cancer incidence. Derivation of standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) for cancer risk comparisons with the general population and rate ratios (RRs) for comparisons with other infertility patients. RESULT(S):
Androgen excess/menstrual disorder patients showed significant SIRs for breast (1.31; 95% CI, 1.05-1.62) and uterine (2.02; 95% CI, 1.13-3.34) cancers and melanoma (1.96; 95% CI, 1.12-3.18). Significant associations for breast and uterine cancers were restricted to primary infertility patients (respective SIRs of 1.53 and 3.48). After adjustment for other cancer predictors, the only excess risk was for uterine cancer among primary infertility patients. Compared with women with secondary infertility and no androgen excess/menstrual disorder, those with primary infertility and a disorder had an RR of 1.88 (95% CI, 0.82-4.32). Cancer risks among the women with polycystic ovary syndrome or androgen excess disorders appeared to be similar to those in the more comprehensive group. CONCLUSION(S): Previous findings linking androgen excess disorders to elevated uterine cancer risks might largely reflect underlying risk profiles.
|
Authors | Louise A Brinton, Kamran S Moghissi, Carolyn L Westhoff, Emmet J Lamb, Bert Scoccia |
Journal | Fertility and sterility
(Fertil Steril)
Vol. 94
Issue 5
Pg. 1787-92
(Oct 2010)
ISSN: 1556-5653 [Electronic] United States |
PMID | 19939368
(Publication Type: Journal Article, Research Support, N.I.H., Intramural)
|
Copyright | Published by Elsevier Inc. |
Topics |
- Adult
- Breast Neoplasms
(epidemiology)
- Cohort Studies
- Female
- Follow-Up Studies
- Humans
- Hyperandrogenism
(complications)
- Incidence
- Infertility, Female
(complications)
- Melanoma
(epidemiology)
- Menstruation Disturbances
(complications)
- Polycystic Ovary Syndrome
(complications)
- Retrospective Studies
- Risk Factors
- Skin Neoplasms
(epidemiology)
- Uterine Neoplasms
(epidemiology)
|